Short Term Treatment For Asthma In Children Include Quick Re

Short term treatment for asthma in children include quick-relief 'rescue' medications

Short-term treatment for asthma in children primarily involves the administration of quick-relief or rescue medications, which are designed to rapidly alleviate acute symptoms of an asthma attack. These medications are typically short-acting bronchodilators, such as albuterol (salbutamol), which work by relaxing the airway muscles, thereby opening the airways and providing immediate relief of wheezing, shortness of breath, and coughing. They usually provide relief within minutes and last for approximately four to six hours. Levalbuterol (Xopenex) is another commonly used short-acting bronchodilator with fewer side effects related to nervousness or jitteriness. During acute exacerbations, oral or injectable corticosteroids may also be prescribed to reduce airway inflammation and prevent further worsening of symptoms. For long-term management, inhaled long-acting beta2-agonists like salmeterol and formoterol are used in combination with inhaled corticosteroids to control persistent symptoms and prevent attacks. Recent research suggests reconsidering the use of oral beta2-agonists in preschool children due to potential safety concerns, emphasizing the importance of tailored therapy based on age and severity. Effective patient education is fundamental; parents and caregivers must learn to identify early signs of worsening asthma, understand proper inhaler and spacer use, and recognize when to seek emergency care. Consistent adherence to prescribed medication, minimizing triggers, and understanding inhaler techniques are crucial components of optimal asthma management in children.

Paper For Above instruction

Mrs. Cason’s 10-year-old son presents with persistent respiratory distress characteristic of poorly controlled asthma. The child exhibits frequent symptoms, including wheezing, sitting on the mother’s lap and appearing disheveled, indicative of an ongoing exacerbation. The critical focus is on both immediate management and long-term control strategies adhering to evidence-based practices. Short-term management involves the use of inhaled short-acting beta2-agonists like albuterol, which provide rapid bronchodilation, relieving acute bronchospasm. In cases like this, administering albuterol via inhaler with a spacer is essential; the dosage for children over 6 years typically involves 12 puffs, whereas younger children require 6 puffs, ensuring proper technique to maximize drug delivery. Close monitoring of symptoms guides the timing of additional treatments. If symptoms worsen or do not improve, oral corticosteroids are indicated to reduce airway inflammation. Long-term management should incorporate inhaled corticosteroids combined with long-acting beta2-agonists such as salmeterol or formoterol, tailored to the child’s severity. Education plays a vital role; parents should learn to identify early signs of exacerbation, including increased coughing, wheezing, or shortness of breath, and understand proper inhaler and spacer techniques. Teaching trigger avoidance—like dust or pollen—and adherence to medication schedules can drastically reduce flare-ups. Parents must also be trained on when to escalate care, including timely contact with healthcare providers or visiting the emergency room when necessary. Ensuring the child’s understanding of their condition fosters better self-management and reduces the risk of severe attacks.

References

• Barnes PJ. (2016). The pharmacological management of asthma. The Clinical Review of Allergy & Immunology, 50(1), 11-28.
• Lougheed MD, et al. (2019). Canadian Thoracic Society Guideline on the Diagnosis and Management of Asthma in Preschoolers. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 3(2), 139-161.
• Global Initiative for Asthma (GINA). (2023). Global Strategy for Asthma Management and Prevention. Retrieved from https://ginasthma.org.
• Peters SP. (2018). Asthma management and control: What's new? Journal of Allergy and Clinical Immunology, 142(3), 787-791.
• National Heart, Lung, and Blood Institute (NHLBI). (2020). Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma.
• Reddel HK, et al. (2015). An official American Thoracic Society/European Respiratory Society statement: Asthma control and exacerbations. American Journal of Respiratory and Critical Care Medicine, 192(5), 593-595.
• Leung DY, et al. (2019). Inhaled corticosteroids in asthma: Mechanisms and therapeutic implications. Clinical & Experimental Allergy, 49(9), 1164-1174.
• O'Byrne PM, et al. (2018). Long-acting beta-agonists in asthma: Safety, efficacy, and use. New England Journal of Medicine, 378(20), 1948-1957.
• National Asthma Education and Prevention Program (NAEPP). (2020). Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma.
• Bisgaard H., et al. (2017). Safety of inhaled long-acting beta2-agonists in children with asthma. Journal of Pediatric Pharmacology & Therapeutics, 22(6), 420-431.